Novartis AG ADR (NVS)vsPluri Inc. (PLUR)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
PLUR
Pluri Inc.
$2.36
-0.84%
HEALTHCARE · Cap: $25.52M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 5243459% more annual revenue ($56.58B vs $1.08M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
PLUR
Avoid13
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for PLUR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PLUR
The strongest argument for PLUR centers on Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : PLUR
The primary concerns for PLUR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while PLUR is a value play — different risk/reward profiles.
PLUR carries more volatility with a beta of 0.75 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 13/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Pluri Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Pluri Inc. is an innovative biotechnology firm specialized in regenerative medicine and immunotherapy, utilizing its proprietary technology platform to develop advanced cell-based therapies for oncology and degenerative diseases. With a strong focus on addressing significant unmet medical needs, Pluri is building a robust pipeline of therapeutics while establishing strategic collaborations within the industry to enhance patient outcomes. The company's commitment to transforming healthcare solutions positions it as a potential leader in the biotech sector, driving growth and delivering impactful advancements in patient care.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?